Anglo-Indian contract research organisation (CRO) Veeda Clinical Research has launched Veeda Oncology as a vehicle to provide oncology clinical research services to the pharmaceutical and biotechnology industries worldwide.

Veeda has been putting in place the infrastructure for its oncology subsidiary since last July. With headquarters in Columbus, Ohio (US), Veeda Oncology will be headed up by Matt Bowman as president and chief executive officer.

According to the parent company, Bowman has more than 20 years’ experience with major pharmaceutical, biotechnology and oncology clinical research companies. Also on the management team are Kathy Squillance, as vice-president of clinical operations, and Dave Colborn as vice-president of data management and information technology.

Bowman said the new subsidiary would supply clients with “world-class oncology expertise along with rapid and cost-effective access to oncology haematology patients around the globe through our facilities in India, Europe and North America”.

A key part of this strategy, noted Apurva Shah, co-group managing director of Veeda Clinical Research, would be providing access to the oncology patient population through “our unique exclusive relationships with oncology hospitals in India as well as unique relationships with oncology hospitals in Eastern Europe”.

In addition, Shah explained, “our US organisation has worked with virtually every major oncology investigational site. With these relationships and the rapid ability to open sites, we will be able to meet the critical accrual requirements that our sponsors are establishing to accelerate the rate of drug development”.

Veeda Oncology will also be looking to boost its global capacity further through “targeted acquisitions that we anticipate completing during the next quarter”, Bowman said.

Last May, Veeda Clinical Research acquired a Phase I clinical research unit in Görlitz, eastern Germany, its second acquisition in Europe following the takeover of Brussels-based CRO DICE in December 2006.